INC Research, a therapeutically focused global CRO with a Trusted Process for delivering reliable results, has appointed Beatrice Setnik, Ph.D., vice president, Clinical Pharmacology. Setnik will support INC Research’s Early Phase Business Unit, providing scientific direction on matters related to abuse liability.

“Setnik’s extensive knowledge and experience in the area of human abuse liability assessment and risk evaluation, as well as in CNS drug development, clinical trial design and strategic lifecycle management, will be instrumental in furthering the development of our abuse potential capabilities and new scientific growth strategies for early phase clinical research,” said Dr. Pierre Geoffroy, vice president, Early Phase at INC Research.

Setnik joins INC Research from Pfizer, most recently as senior director, Medical Development-Neuroscience, where she led clinical development, including abuse potential evaluation of several opioid formulations. Previously, she worked as a research scientist providing scientific input on specialty phase I-II clinical trials, including abuse potential studies.

Setnik chairs the clinical sub-team within the Cross Company Abuse Liability Consortium and has been an active member in the group since 2008. She also is an active participant in several congresses including the College on Problems of Drug Dependence. Setnik has been actively engaged in many aspects of abuse potential assessment, including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.